Figure 1
From: Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease
Enhancing norepinephrine may be a promising strategy to treat Alzheimer's disease. (a) Plaque deposition in the hippocampus (HP) and cortex (CTX) of 1-year-old APP/PS1 mice (NET WT,APP/PS1) and norepinephrine transporter knockout APP/PS1 mice (NET KO,APP/PS1) as detected by immunohistochemistry using antiserum 2964 against fibrillar Aβ42. (b) Abundance of full-length amyloid precursor protein (APP), the APP C-terminal fragment (CTF), and Aβ in male and female NET WT,APP/PS1 and NET KO,APP/ PS1 mice at 6 months of age as detected by western blot using mAb 6E10 against amino acid residues 1 to 16 of Aβ. Tubulin was used as a loading control. Aβ, amyloid-beta; NET WT, norepinephrine transporter wildtype; PS1, presenilin-1.